brazikumab
mAbexperimental
Brazikumab is a human monoclonal antibody designed for the treatment of Crohn's disease. It targets IL-23. — Wikipedia
Clinical trial activity
9 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
5
Phase 3
2
Phase 4
0
Earliest trial started Apr 11, 2010 (NCT01094093)
Timeline
Indications
Mechanism of action
- Interleukin-23 subunit alphaINHIBITOR
IL23A inhibitor
- Interleukin-37INHIBITOR
IL37 inhibitor
- Interleukin-23INHIBITOR
Interleukin-23 inhibitor
Alpha (p19) subunit is binding site
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3833372 ↗
- WikipediaBrazikumab ↗
- ChEMBLCHEMBL2109627 ↗
- ChEMBLCHEMBL2109609 ↗
Also known as
- amg 139
- amg-139
- medi2070
- medi-2070
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05033431 | Phase 1 | Oct 11, 2021 | AstraZeneca |
| NCT04277546 | Phase 2 | Feb 18, 2020 | Allergan |
| NCT03961815 | Phase 3 | May 29, 2019 | Allergan |
| NCT03759288 | Phase 2/Phase 3 (Phase 3) | Dec 7, 2018 | Allergan |
| NCT03616821 | Phase 2 | Aug 7, 2018 | Allergan |
| NCT02574637 | Phase 2 | Jan 5, 2016 | Allergan |
| NCT01714726 | Phase 2 | Feb 1, 2013 | Allergan |
| NCT01258205 | Phase 1 | Feb 28, 2011 | Allergan |
| NCT01094093 | Phase 1 | Apr 11, 2010 | Allergan |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Allergan | For profit | 8 | 8 | 3 | 2010 |
| AstraZeneca | For profit | 1 | 1 | 1 | 2021 |
2 organizations
Page 1 / 1